ClinicalTrials.gg
CompletedNCT00558038AST015Updated May 30, 2014

Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy

A Phase 2 interventional study of AST-120 and lactulose in Hepatic Encephalopathy, sponsored by Ocera Therapeutics. Completed at 17 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-05-30.

Sponsored by Ocera Therapeutics (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Hepatic Encephalopathy with a site in United States — 9 open to participants now, 13 under way, 1 of them phase 3. Hepatic Encephalopathy · United States.

Enrollment
28th of 58
40 · median 39
Started
2007
with 3 others
Phase 2
18 of 70
1 open now
Registered
6th of 70
by date
Lead sponsor
2 of 70
Ocera Therapeutics

Among the 70 studies in Hepatic Encephalopathy with a site in United States, this one is the 28th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2007, is one of 18 in phase 2, and was the 6th registered.

Hepatic Encephalopathy

225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.

Browse Hepatic Encephalopathy studies →

Open to participants now

9 of the 70 studies in Hepatic Encephalopathy with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Hepatic Encephalopathy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 compared to lactulose in patients with mild hepatic encephalopathy.

Read the detailed description

This is a multi-center, open-label, four week trial comparing AST-120 to lactulose in patients with mild (Stage 1-2) hepatic encephalopathy.

Patients will be randomized into two groups:

  • Lactulose
  • AST-120

Patients meeting the inclusion criteria will take either AST-120 or lactulose for 4 weeks (28 days). AST-120 will be distributed in 2 gram sachets to be taken four times daily. Lactulose will be taken in the same formulation, at the same dose and frequency as previously prescribed for the individual patient.

Lactulose naïve patients who are randomized to lactulose will receive an initial dose of 30cc twice a day. The dose should be titrated at the discretion of the investigator until the patient is experiencing 2-3 soft stools per day.

Patients randomized to AST-120 will receive 2 grams four times a day for the duration of the study. Titration of AST-120 will NOT be allowed.

Patients will be evaluated throughout the study for efficacy and safety. A follow-up visit will be scheduled 1 week after the end of the 4 week treatment period.

03

Conditions studied

  • Hepatic Encephalopathy

Keywords

  • Hepatic
  • Encephalopathy
  • Liver
  • Liver Disease
  • Liver Failure
  • Lactulose
  • AST-120
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with End Stage Liver Disease secondary to any cause (patients who have undergone portosystemic shunting (TIPS) procedure > 3 months prior to randomization can be included)
  • Lactulose naïve patients or patients currently on an established dose of lactulose
  • MELD score ≤ 15 (MELD score up to 20 is allowable if it has remained stable for at least 3 months)
  • Meet the criteria for Stage 1-2 hepatic encephalopathy according to the Westhaven Scale
  • Patients must have discontinued rifaximin or other oral antibiotics for at least 48 hours prior to randomization
  • Able and willing to comply with all protocol procedures for the planned duration of the study
  • Able and willing to understand, sign and date an document, and authorize access to protected health information
  • Have a person (spouse, relative, or friend) willing to accompany the patient to the study visits (patients in this condition are not recommended to drive a vehicle)
  • Females must be , surgically incapable of bearing children, or practicing a reliable method of (intrauterine devices, spermicide and barrier). Partner/spouse sterility may also qualify at the investigator's discretion. Females of must have a negative urine pregnancy test at baseline.

Note: Patients already on lactulose and randomized to -120 will stop taking lactulose on the day they begin taking AST-120.

Exclusion criteria

Exclusion Criteria:

  • Patients whose condition necessitates continuous administration of antibiotics (e.g. rifaximin, neomycin, metronidazole)
  • Patients undergoing chemotherapy for treatment of cancer (patients with hepatocellular carcinoma being treated by methods other than chemotherapy may be enrolled)
  • Patients who require continued treatment with narcotics or sedatives
  • Patients who have active GI bleeding
  • Patients who have an active infection
  • Patients who have signs and symptoms of severe dehydration
  • Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling
  • Unable to attend all visits required by the protocol
  • Female patients must be EXCLUDED if they are pregnant, breast feeding, planning to become pregnant during the study or using hormonal as their only method of birth control
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    1

    Drug: lactulose

  • Experimental
    2

    Drug: AST-120

Interventions

  • DrugAST-120

    Drug pages: AST 120 · Charcoal

    AST-120

  • lactulose

    Also known as: Chronulac, Constilac, Constulose, Duphalac, Evalose

06

What researchers measure

Primary outcomes

  1. Change in Westhaven Scale

    Time frame: 4 weeks

Secondary outcomes

  1. Efficacy: Change in Hepatic Encephalopathy Scoring Algorithm (HESA)

    Time frame: 4 weeks

  2. Efficacy: Reduction of venous ammonia levels

    Time frame: 4 weeks

  3. Efficacy: Serum bile acids and amino acid profile

    Time frame: 4 weeks

  4. Efficacy: Reduction in itching (visual analog scale)

    Time frame: 4 weeks

  5. Efficacy: Presence or absence of asterixis

    Time frame: 4 weeks

  6. Safety: Clinical laboratory tests

    Time frame: 4 weeks

  7. Safety: Physical examination, vital signs (blood pressure, heart rate, respiration rate, body temperature)

    Time frame: 4 weeks

07

Study locations

17 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Scripps Clinic
    San Diego, California 92037, United States
  • Veterans Medical Center San Diego
    San Diego, California 92161, United States
  • Washington Hospital Center - MedStar Research Institute
    Washington, District of Columbia 20010, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • University of Massachusetts Medical School
    Worchester, Massachusetts 01655, United States
  • Weill Medical College of Cornell
    New York, New York 10021, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Baylor University Medical Center
    Houston, Texas 77030, United States
  • St. Luke's Advanced Liver Therapies / St. Luke's Texas Liver Coalition - Baylor College of Medicine
    Houston, Texas 77030, United States
  • Metropolitan Research
    Fairfax, Virginia 22031, United States
  • McGuire VA Medical Center
    Richmond, Virginia 23249, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Mar 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2007
First posted
Nov 14, 2007
Start
Sep 2007
Primary completionActual
Mar 2009
CompletionActual
Jun 2009
Results delay requested
Jul 26, 2013
Last update
May 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00558038
Lead sponsor
Ocera Therapeutics
Responsible party
Sponsor
First posted
Nov 14, 2007
Start date
Sep 2007
Primary completion
Mar 2009
Completion
Jun 2009
Last update
May 30, 2014

Study contacts

Paul Pockros, MD
principal investigator · Scripps Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AST 120 · Charcoal

Start the discussion